Molecular Components of Wnt/β-catenin Pathway As Therapeutic Targets For Upper Gastrointestinal Cancers

Author(s): Nikki P. Lee, Zhi Xu, Sarwat Fatima, Timothy T. Yung, Raymond W. Y. Sun, Simon Law

Journal Name: Clinical Cancer Drugs

Volume 2 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Background: Worldwide, esophageal and gastric cancers are the two most frequent cancers associated with the upper gastrointestinal tract. These two types of cancers alone account for nearly a million deaths annually. Most patients when first diagnosed are already in advanced stage of the disease, where frontline treatments such as surgical resection are ineffective. Alternative treatments such as chemotherapy, radiotherapy and targeted therapies are the remaining options for this group of inoperable patients, though each of these treatment options has its own limitations and disadvantages. Discussion: To improve current cancer management, new treatment directions are needed. In the recent decade, Wnt/β-catenin pathway is emerging as a hallmark of various types of malignancies including esophageal and gastric cancers. Its activation is manifested by alteration and deregulation of the core components of this pathway. Conclusion: Identification of key deregulated components along this pathway has opened up a new avenue of research to combat esophageal and gastric cancers by targeting these components to counteract tumorigenesis.

Keywords: Wnt, esophageal cancer, gastric cancer, therapeutic target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [72 - 79]
Pages: 8
DOI: 10.2174/2212697X02666151028192148
Price: $25

Article Metrics

PDF: 47